Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...

Facing steep competition, Novo Nordisk has slashed the price for its weight loss drug Wegovy — temporarily, at least.

That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.